Literature DB >> 30819904

Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.

Dylan Graetz1, Kristine R Crews2, Elizabeth M Azzato3, Ravi K Singh3, Susana Raimondi3, John Mason3, Marcus Valentine4, Charles G Mullighan3, Ashley Holland1, Hiroto Inaba1, Vasiliki Leventaki5,6.   

Abstract

Entities:  

Year:  2019        PMID： 30819904      PMCID： PMC6518893          DOI： 10.3324/haematol.2018.215103

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.

Authors:  Carlo Gambacorti-Passerini; Lara Mussolin; Laurence Brugieres
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

Review 2.  Poly(A)-binding proteins: structure, domain organization, and activity regulation.

Authors:  I A Eliseeva; D N Lyabin; L P Ovchinnikov
Journal:  Biochemistry (Mosc)       Date:  2013-12       Impact factor: 2.487

3.  Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.

Authors:  Laurence Lamant; Keith McCarthy; Emanuele d'Amore; Wolfram Klapper; Atsuko Nakagawa; Maximo Fraga; Jadwiga Maldyk; Ingrid Simonitsch-Klupp; Ilske Oschlies; Georges Delsol; Audrey Mauguen; Laurence Brugières; Marie-Cécile Le Deley
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

Review 4.  ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis. Report of three cases and review of the literature.

Authors:  Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Sheila Moore; Emma L Harwood; Ching-Hon Pui; John T Sandlund
Journal:  Am J Clin Pathol       Date:  2003-10       Impact factor: 2.493

Review 5.  Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature.

Authors:  Jaspreet S Grewal; Lauren B Smith; Jerome D Winegarden; John C Krauss; Joseph A Tworek; Bertram Schnitzer
Journal:  Ann Hematol       Date:  2007-03-30       Impact factor: 3.673

6.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

Review 7.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

8.  Identification of a C-terminal poly(A)-binding protein (PABP)-PABP interaction domain: role in cooperative binding to poly (A) and efficient cap distal translational repression.

Authors:  Eduardo O Melo; Rafael Dhalia; Cezar Martins de Sa; Nancy Standart; Osvaldo P de Melo Neto
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

9.  Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

Authors:  Jo-Anne van der Krogt; Marlies Vanden Bempt; Julio Finalet Ferreiro; Nicole Mentens; Kris Jacobs; Ursula Pluys; Kathleen Doms; Ellen Geerdens; Anne Uyttebroeck; Pascal Pierre; Lucienne Michaux; Timothy Devos; Peter Vandenberghe; Thomas Tousseyn; Jan Cools; Iwona Wlodarska
Journal:  Haematologica       Date:  2017-06-28       Impact factor: 9.941

10.  Characterization of the multimeric structure of poly(A)-binding protein on a poly(A) tail.

Authors:  Ryoichi Sawazaki; Shunsuke Imai; Mariko Yokogawa; Nao Hosoda; Shin-Ichi Hoshino; Muneyo Mio; Kazuhiro Mio; Ichio Shimada; Masanori Osawa
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.